Understanding Apellis Pharmaceuticals – A Fundamental Overview

By Scott Lee • Tuesday, February 27 10:11 • Permanent Link

One of the losers of today's trading session was Apellis Pharmaceuticals. Shares of the Pharmaceutical company plunged -7.2%, and some investors may be wondering if its price of $66.57 would make a good entry point. Here's what you should know if you are considering this investment:

Apellis Pharmaceuticals has moved 9.5% over the last year, and the S&P 500 logged a change of 27.7%
APLS has an average analyst rating of buy and is -16.71% away from its mean target price of $79.93 per share
Its trailing earnings per share (EPS) is $-5.23
Apellis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -12.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.01 and its forward P/E ratio is -65.9
The company has a Price to Book (P/B) ratio of 33.93 in contrast to the S&P 500's average ratio of 2.95
Apellis Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-425164128, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.